Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

EASD
Virtual
2021
Meet the Experts
Date and time:
30.09.2021 at 09:15 - 09:45 CEST
Type:
Corporate Event
Speakers:
Lise Lotte Gluud; Elmar Jaeckel;
Congress:
European Association for the Study of Diabetes (EASD)
Industry session on the occasion of the 57th Annual Meeting of the European Association for the Study of Diabetes. Nonalcoholic steatohepatitis (NASH) is the most severe form of nonalcoholic fatty liver disease (NAFLD) and represents a significant burden for patients as well as increases the risk of overall and liver-related mortality. Being closely linked to the obesity and diabetes epidemics, NAFLD/NASH prevalence has been rising globally, although, effective diagnosis and monitoring of patients with the condition remains suboptimal. Due to the close link between NASH and type 2 diabetes, endocrinologists have an important role in identifying these patients. During this meet the expert session - The global rise of NASH and liver fibrosis - what can we do? - we will hear perspectives from an expert endocrinologist (Elmar Jaeckel) and hepatologist (Lise Lotte Gluud) on the importance of identifying patients at high risk of progressive NASH as well as the practicalities of doing this. They will also discuss the key role of interdisciplinary collaboration for the management of NASH to help improve patient outcomes.

How and why to identify high-risk patients: lessons from the clinic

The future of NASH: the importance of interdisciplinary collaboration (interactive Q&A)

Elmar Jaeckel - Speaker

Elmar Jaeckel

Hannover Medical School, Hannover, Germany


Elmar Jaeckel is a medical doctor in the Department of Gastroenterology, Hepatology & Endocrinology at the Hannover Medical School, Hannover, Germany. He received his training in Hamburg, Germany; Yale New Haven, New Haven, CT, USA; the University of California San Diego, CA, USA; the University of Edinburgh, Edinburgh, UK; and the University of Sydney, Sydney, Australia. Dr Jaeckel spent 4 years as a postdoctoral fellow at the Joslin Diabetes Center of the Harvard Medical School, Boston, MA, USA. He is the attending endocrinologist and diabetologist at the Hannover Medical School.

 

Dr Jaeckel’s working group, Immune Tolerance, aims to establish immune tolerance in type 1 diabetes and after biological beta-cell replacement. For this purpose, he is developing new cell and gene therapy approaches. Dr Jaeckel is involved in pursuing islet xenotransplantation in Germany. He is also studying non-alcoholic steatohepatitis (NASH) in animal models and patient material and is developing incretin-based therapies for NASH.


Read full bio
Lise Lotte Gluud - Speaker

Lise Lotte Gluud

University of Copenhagen, Copenhagen, Denmark


Professor Lise L Gluud is a consultant gastroenterologist and professor of gastroenterology and hepatology. Her main research areas include lifestyle-associated liver diseases focusing on non-alcoholic steatohepatitis as well as cirrhosis-related complications. Other areas of interest include inflammatory and metabolic complications associated with pancreatitis. Professor Gluud is a member of the European Foundation for the Study of Chronic Liver Failure Steering Committee, and the national representative in the Prospective European Drug-Induced Liver Injury Network Management Committee.

 

Other qualifications include: Specially Appointed Named Person at the Faculty of Health and Medical Sciences, University of Copenhagen, Member of the National Committee on Health Research Ethics; Chairman of the National Clinical Guideline for the management of patients with non-alcoholic fatty liver disease; Chairman of the Danish Association of Gastroenterology and Hepatology (DSGH) Guideline Committee; Member of DSGH Research Committee; PLoS One Section Editor; and Editor Cochrane Hepato-Biliary Group.


Read full bio

Related